No business profile yet.
Size Medigen Vaccine Biologics (6547.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $424M, the 487th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$44.10 on 18 Nov 2026.
Performance Over six months the shares fell 7.9%, against -22.0% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 44.4% over the last twelve months (peer median +1.7%); the operating margin is -4.5% (peer median -12.8%).
Valuation It trades at 170.0× forward earnings against a peer median of 26.2× (most expensive of 6).
Capital Return on invested capital runs 6.1 points below its cost of capital (5.0% WACC).
Next results Next results expected around 12 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$859M | NT$613M | NT$606M | NT$390M | NT$365M |
| Revenue growth | — | +1% | +55% | +7% | — |
| Gross profit | NT$447M | NT$312M | NT$332M | NT$221M | -NT$221M |
| EBITDA | NT$110M | -NT$124M | -NT$9.23M | -NT$1.08B | -NT$1.41B |
| Net income | -NT$34.9M | -NT$282M | -NT$80.5M | -NT$1.16B | -NT$1.47B |
| Free cash flow | -NT$428M | -NT$99.7M | NT$6.46M | -NT$516M | -NT$1.24B |
| Capital expenditure | NT$387M | NT$51.8M | NT$35.0M | NT$41.0M | NT$140M |
| Total debt | NT$540M | NT$283M | NT$339M | NT$1.97B | NT$1.98B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6547.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.3% | -12.4% | 8th lowest of 21 |
| 6-month return | -7.9% | -22.0% | 7th highest of 21 |
| Distance from 52-week high | -38.9% | -43.6% | 9th highest of 21 |
| Revenue growth (TTM) | +44.4% | +1.7% | 6th highest of 17 |
| Operating margin | -4.5% | -12.8% | 8th highest of 17 |
| Forward P/E | 170.0× | 26.2× | most expensive of 6 |
| ROIC minus cost of capital | -6.1 pp | -11.2 pp | 7th highest of 16 |
| Net debt / EBITDA | -12.9× | -2.6× | least indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $424M | -8% | +44% | -5% | 170.0× | n/a | n/a |
| Shanghai ZJ Bio-Tech 688317.SS | China | $422M | -22% | -10% | -72% | n/a | 4.0% | -62.3% |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $427M | +11% | +13% | 47% | 26.2× | 5.3% | +70.5% |
| Qyuns Therapeutics 2509.HK | Hong Kong | $428M | -11% | +230% | 56% | 10.2× | -19.5% | n/a |
| Prothena PRTA | United States | $429M | -11% | +347% | -73% | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $418M | -76% | -65% | -1,112% | n/a | n/a | n/a |
| Candel Therapeutics CADL | United States | $417M | -31% | n/a | n/a | n/a | n/a | n/a |
| G2GBIO 456160.KS | South Korea | $416M | -53% | -45% | -2,884% | n/a | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $416M | -34% | -1% | 26% | n/a | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $416M | +1% | n/a | n/a | n/a | n/a | n/a |
| Scinopharm Taiwan 1789.TW | Taiwan | $435M | -2% | -5% | -4% | 39.4× | 2.1% | +0.5% |
| Shanghai Obio Technology (Group) 688238.SS | China | $414M | -5% | +20% | -79% | n/a | n/a | n/a |
| Qingdao Vland Biotech 603739.SS | China | $437M | -24% | +5% | 7% | 33.9× | 7.7% | +7.3% |
| Berry Genomics 000710.SZ | China | $439M | -17% | -2% | -24% | n/a | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $410M | -35% | +1,418% | 26% | n/a | -15.3% | +197.3% |
| IRulya Therapeutics IRLA | United States | $440M | +88% | n/a | n/a | n/a | n/a | n/a |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $409M | -24% | n/a | n/a | n/a | n/a | n/a |
| Arvinas ARVN | United States | $443M | -26% | -12% | -10% | n/a | n/a | n/a |
| EirGenix 6589.TW | Taiwan | $444M | +15% | +58% | -51% | n/a | n/a | n/a |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $404M | -24% | +286% | 68% | 5.7× | -18.8% | -36.1% |
| Shanghai Shen Lian Biomedical 688098.SS | China | $402M | -22% | -17% | -16% | n/a | n/a | n/a |